Status:
COMPLETED
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
Lead Sponsor:
Peking University Third Hospital
Conditions:
Stereotactic Body Radiotherapy
PD-1 Inhibitors
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC. The patients, diagnosed with locally adv...
Detailed Description
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with PD-1 blockers for LAPC and LRPC. The patients, diagnosed with loca...
Eligibility Criteria
Inclusion
- LRPC confirmed by pathologic or imaging diagnosis and LAPC confirmed by pathology;
- disease size ≥1 cm;
- KPS≥70;
- adequate hematological reserves, hepatic function, renal function and heart function;
- expected survival \> 3 months.
Exclusion
- unconfirmed mass;
- The upper abdomen was previously treated with radiotherapy;
- the patients previously underwent immunotherapy of PD-1 or PD-L1 monoclonal antibody;
- a history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency or other immune-related conditions requiring long-term oral hormone therapy;
- patients with active infectious disease, trauma and severe wounds;
- patients with any mental disorder;
- patients with other somatic comorbidities of clinical concern;
- pregnancy and lactation.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT06195254
Start Date
December 1 2020
End Date
December 15 2023
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Junjie Wang
Beijing, Beijing Municipality, China, 100191